{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:27:06Z","timestamp":1790684826293,"version":"4.1.0"},"reference-count":27,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2019,8,10]],"date-time":"2019-08-10T00:00:00Z","timestamp":1565395200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002661","name":"Fonds De La Recherche Scientifique - FNRS","doi-asserted-by":"publisher","award":["J.0220.16"],"award-info":[{"award-number":["J.0220.16"]}],"id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002661","name":"Fonds De La Recherche Scientifique - FNRS","doi-asserted-by":"publisher","award":["T.0013.19"],"award-info":[{"award-number":["T.0013.19"]}],"id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002661","name":"Fonds De La Recherche Scientifique - FNRS","doi-asserted-by":"publisher","award":["The Excellence Of Science: EOS 30770923"],"award-info":[{"award-number":["The Excellence Of Science: EOS 30770923"]}],"id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002661","name":"Fonds De La Recherche Scientifique - FNRS","doi-asserted-by":"publisher","award":["WELBIO-CR-2017-C02"],"award-info":[{"award-number":["WELBIO-CR-2017-C02"]}],"id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010563","name":"Funds Baillet Latour","doi-asserted-by":"crossref","award":["Grant for Medical Research 2015"],"award-info":[{"award-number":["Grant for Medical Research 2015"]}],"id":[{"id":"10.13039\/501100010563","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Gut"],"accepted":{"date-parts":[[2019,7,28]]},"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To fulfil an unmet therapeutic need for treating type 2 diabetes by developing an innovative oral drug delivery nanosystem increasing the production of glucagon-like peptide-1 (GLP-1) and the absorption of peptides into the circulation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>We developed a nanocarrier for the oral delivery of peptides using lipid-based nanocapsules. We encapsulated the GLP-1 analogue exenatide within nanocapsules and investigated in vitro in human L-cells (NCl-H716) and murine L-cells (GLUTag cells) the ability of the nanosystem to trigger GLP-1 secretion. The therapeutic relevance of the nanosystem in vivo was tested in high-fat diet (HFD)-induced diabetic mice following acute (one administration) or chronic treatment (5 weeks) in obese and diabetic mice.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We demonstrated that this innovative nanosystem triggers GLP-1 secretion in both human and murine cells as well as in vivo in mice. This strategy increases the endogenous secretion of GLP-1 and the oral bioavailability of the GLP-1 analogue exenatide (4% bioavailability with our nanosystem).<\/jats:p>\n                  <jats:p>The nanosystem synergizes its own biological effect with the encapsulated GLP-1 analogue leading to a marked improvement of glucose tolerance and insulin resistance (acute and chronic). The chronic treatment decreased diet-induced obesity, fat mass, hepatic steatosis, together with lower infiltration and recruitment of immune cell populations and inflammation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>We developed a novel nanosystem compatible with human use that synergizes its own biological effect with the effects of increasing the bioavailability of a GLP-1 analogue. The effects of the formulation were comparable to the results observed for the marketed subcutaneous formulation. This nanocarrier-based strategy represents a novel promising approach for oral peptide delivery in incretin-based diabetes treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/gutjnl-2019-319146","type":"journal-article","created":{"date-parts":[[2019,8,10]],"date-time":"2019-08-10T17:15:13Z","timestamp":1565457313000},"page":"911-919","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":64,"title":["Novel strategy for oral peptide delivery in incretin-based diabetes treatment"],"prefix":"10.1136","volume":"69","author":[{"given":"Yining","family":"Xu","sequence":"first","affiliation":[{"name":"Advanced Drug Delivery and Biomaterials, Louvain Drug Research Institute (LDRI), UCLouvain, Universit\u00e9 catholique de Louvain, Bruxelles, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Van Hul","sequence":"additional","affiliation":[{"name":"Metabolism and Nutrition Research group, Louvain Drug Research Institute (LDRI), UCLouvain, Universit\u00e9 catholique de Louvain, Brussels, Belgium"},{"name":"WELBIO, Walloon Excellence in Life Sciences and BIOtechnology, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Suriano","sequence":"additional","affiliation":[{"name":"Metabolism and Nutrition Research group, Louvain Drug Research Institute (LDRI), UCLouvain, Universit\u00e9 catholique de Louvain, Brussels, Belgium"},{"name":"WELBIO, Walloon Excellence in Life Sciences and BIOtechnology, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Pr\u00e9at","sequence":"additional","affiliation":[{"name":"Advanced Drug Delivery and Biomaterials, Louvain Drug Research Institute (LDRI), UCLouvain, Universit\u00e9 catholique de Louvain, Bruxelles, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2040-2448","authenticated-orcid":false,"given":"Patrice D","family":"Cani","sequence":"additional","affiliation":[{"name":"Metabolism and Nutrition Research group, Louvain Drug Research Institute (LDRI), UCLouvain, Universit\u00e9 catholique de Louvain, Brussels, Belgium"},{"name":"WELBIO, Walloon Excellence in Life Sciences and BIOtechnology, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Beloqui","sequence":"additional","affiliation":[{"name":"Advanced Drug Delivery and Biomaterials, Louvain Drug Research Institute (LDRI), UCLouvain, Universit\u00e9 catholique de Louvain, Bruxelles, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,8,10]]},"reference":[{"key":"2025090715132480000_69.5.911.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2016.02.004"},{"key":"2025090715132480000_69.5.911.2","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.addr.2016.02.011","article-title":"Oral delivery of diabetes peptides - comparing standard formulations incorporating functional excipients and nanotechnologies in the translational context","volume":"106","author":"Lakkireddy","year":"2016","journal-title":"Adv Drug Deliv Rev"},{"key":"2025090715132480000_69.5.911.3","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.addr.2018.07.009","article-title":"Battle of GLP-1 delivery technologies","volume":"130","author":"Yu","year":"2018","journal-title":"Adv Drug Deliv Rev"},{"key":"2025090715132480000_69.5.911.4","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.2174\/1381612822666151216150238","article-title":"Delivery of peptides via the oral route: diabetes treatment by peptide-loaded nanoparticles","volume":"22","author":"Bouttefeux","year":"2016","journal-title":"Curr Pharm Des"},{"key":"2025090715132480000_69.5.911.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2016.10.005"},{"key":"2025090715132480000_69.5.911.6","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.addr.2013.01.002","article-title":"Targeted nanoparticles with novel non-peptidic ligands for oral delivery","volume":"65","author":"des Rieux","year":"2013","journal-title":"Adv Drug Deliv Rev"},{"key":"2025090715132480000_69.5.911.7","doi-asserted-by":"crossref","DOI":"10.1186\/1758-5996-6-70","article-title":"Effects of high-fat diet and the anti-diabetic drug metformin on circulating GLP-1 and the relative number of intestinal L-cells","volume":"6","author":"Kappe","year":"2014","journal-title":"Diabetol Metab Syndr"},{"key":"2025090715132480000_69.5.911.8","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.03.054"},{"key":"2025090715132480000_69.5.911.9","doi-asserted-by":"publisher","DOI":"10.1210\/en.2013-1142"},{"key":"2025090715132480000_69.5.911.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2013.03.003"},{"key":"2025090715132480000_69.5.911.11","doi-asserted-by":"publisher","DOI":"10.2337\/dcS13-2037"},{"key":"2025090715132480000_69.5.911.12","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1021\/acs.molpharmaceut.6b00871","article-title":"A mechanistic study on Nanoparticle-Mediated glucagon-like peptide-1 (GLP-1) secretion from enteroendocrine L cells","volume":"13","author":"Beloqui","year":"2016","journal-title":"Mol Pharm"},{"key":"2025090715132480000_69.5.911.13","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1039\/C7NR07736J","article-title":"The stimulation of GLP-1 secretion and delivery of GLP-1 agonists via nanostructured lipid carriers","volume":"10","author":"Shrestha","year":"2018","journal-title":"Nanoscale"},{"key":"2025090715132480000_69.5.911.14","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1021\/acs.molpharmaceut.7b00742","article-title":"Size effect on lipid Nanocapsule-Mediated GLP-1 secretion from enteroendocrine L cells","volume":"15","author":"Xu","year":"2018","journal-title":"Mol Pharm"},{"key":"2025090715132480000_69.5.911.15","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.ijpharm.2009.05.069","article-title":"The gastrointestinal stability of lipid nanocapsules","volume":"379","author":"Roger","year":"2009","journal-title":"Int J Pharm"},{"key":"2025090715132480000_69.5.911.16","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-s249"},{"key":"2025090715132480000_69.5.911.17","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.9.2322"},{"key":"2025090715132480000_69.5.911.18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2008.02514.x"},{"key":"2025090715132480000_69.5.911.19","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-019-0168-8"},{"key":"2025090715132480000_69.5.911.20","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.metabol.2017.04.005","article-title":"Macrophage functions in lean and obese adipose tissue","volume":"72","author":"Thomas","year":"2017","journal-title":"Metabolism"},{"key":"2025090715132480000_69.5.911.21","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200319246"},{"key":"2025090715132480000_69.5.911.22","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.cmet.2014.06.008","article-title":"A macrophage NBR1-MEKK3 complex triggers JNK-mediated adipose tissue inflammation in obesity","volume":"20","author":"Hernandez","year":"2014","journal-title":"Cell Metab"},{"key":"2025090715132480000_69.5.911.23","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2008.165886"},{"key":"2025090715132480000_69.5.911.24","doi-asserted-by":"publisher","DOI":"10.1023\/A:1016121319668"},{"key":"2025090715132480000_69.5.911.25","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-08051-7","article-title":"Intestinal epithelial N-acylphosphatidylethanolamine phospholipase D links dietary fat to metabolic adaptations in obesity and steatosis","volume":"10","author":"Everard","year":"2019","journal-title":"Nat Commun"},{"key":"2025090715132480000_69.5.911.26","doi-asserted-by":"publisher","DOI":"10.1007\/s10858-011-9570-9"},{"key":"2025090715132480000_69.5.911.27","doi-asserted-by":"publisher","DOI":"10.2337\/db15-0060"}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gutjnl-2019-319146","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T22:13:35Z","timestamp":1757283215000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gutjnl-2019-319146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,10]]},"references-count":27,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,4,3]]},"published-print":{"date-parts":[[2020,5]]}},"alternative-id":["10.1136\/gutjnl-2019-319146"],"URL":"https:\/\/doi.org\/10.1136\/gutjnl-2019-319146","relation":{},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,10]]}}}